Amal Hasan, a Mohammad R. Al-Mulla, b Jehad Abubaker, c and Fahd Al-Mulla d
doi: 10.1080/21645515.2021.1969855
PDF: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8459929/pdf/KHVI_0_1969855.pdf
ABSTRACT
Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that target mutant-specific spike proteins along with ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as memory CD8+T-cell immunity.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.